e-learning
resources
Milan 2017
Sunday, 10.09.2017
Primary care diagnosis, assessment and management of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK
N. Roche (Paris, France)
Source:
International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Session:
Primary care diagnosis, assessment and management of COPD
Session type:
Thematic Poster
Number:
937
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Roche (Paris, France). Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK. 937
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Real-life effectiveness of budesonide/formoterol for the management of asthma and COPD
Source: International Congress 2016 – Clinical characteristics of asthma
Year: 2016
A new budesonide/formoterol inhalation therapy in patients with asthma, COPD and ACOS
Source: International Congress 2017 – Bronchial asthma management
Year: 2017
FORWARD: A study of extrafine beclomethasone/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Economic evaluation of beclomethasone/formoterol versus budesonide/formoterol in the treatment of patient with moderate-severe asthma in Spain
Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment
Year: 2008
Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Cost effectiveness of budesonide/formoterol vs fluticasone/salmeterol: Real-world effectiveness and safety in COPD
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Description of the UK’s asthma and COPD inhaler use
Source: International Congress 2018 – Epidemiology of COPD : from exarcebations and comorbidities to asthma-COPD overlap syndrome (ACOS)
Year: 2018
Safety of once-daily glycopyrronium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma
Source: Eur Respir J 2008; 31: 982-989
Year: 2008
Efficacy and safety of extrafine glycopyrronium bromide pMDI (CHF 5259) in COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Onbrace: A real-life evaluation of indacaterol maintenance treatment for COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
The DACCORD study: Real-life COPD outpatient treatment with long-acting bronchodilators in Germany
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013
Efficacy of the using budesonide/formoterol in patients with bronchial asthma (BA): the study of routine clinical practice
Source: Eur Respir J 2006; 28: Suppl. 50, 499s
Year: 2006
A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept